Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Chugai announces development and marketing agreement for osteoporosis drug

Chugai announces development and marketing agreement for osteoporosis drug

19th May 2008

Chugai Pharmaceutical has announced that it has signed an agreement with Taisho Pharmaceutical for the co-development and marketing of an activated vitamin D derivative known as ED-71 (eldecalcitol).

Under the terms of the agreement, Taisho will pay Chugai an upfront fee as well as additional milestone payments.

Chugai is currently developing the drug in Japan for the treatment of osteoporosis, with a phase II clinical trial confirming its strong action to increase bone mass.

A phase III trial of the compound using bone fracture prevention as the indicator is currently ongoing.

The drug is forecast to become the next-generation activated vitamin D derivative that will offer enhanced bone resorption inhibition and promotion of bone formation while maintaining the same level of safety as existing drugs.

“Through the joint effort to develop and market ED-71, Chugai and Taisho hope to provide one of the options of osteoporosis treatment to as many patients as possible,” Chugai said.

It added that this agreement will have a minor impact on the consolidated and non-consolidated business performances of both firms for this financial year, with no changes being made to their business forecasts.

Last month, Chugai announced a restructuring of its European sales bases with the goal of improving and strengthening its marketing activities in the region.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.